MICHAEL J. P. LAWMAN,PATRICIA D. LAWMAN,VIJAY RAMIYA,MEGHAN GENTILINI
申请号：
US16551138
公开号：
US20200000901A1
申请日:
2019.08.26
申请国别(地区):
US
年份:
2020
代理人:
摘要：
Customized whole cell cancer vaccines can be produced from autologous (ex vivo or in situ) or allogeneic human or veterinary patient cell lines. Cells are transformed with S. pyogenes DNA that expresses an Emm protein on the cell surface and cytosol. Treatment of cancer patients with an Emm vector vaccine induces an immunologic response to the cancer by enhancing immunogenicity of a tumor. Emm vaccines can be used in patients where the cancer is not identified due to lower tumor burden or used to treat a specific cancer and subsequently treat for a second type that may have arisen through metastasis.
